Edition:
United States

Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

1.13USD
3:59pm EST
Change (% chg)

$-0.04 (-3.42%)
Prev Close
$1.17
Open
$1.17
Day's High
$1.17
Day's Low
$1.12
Volume
54,574
Avg. Vol
104,389
52-wk High
$2.89
52-wk Low
$1.02

Latest Key Developments (Source: Significant Developments)

Athersys reports pricing of public offering of common stock
Friday, 27 Jan 2017 09:00am EST 

Athersys Inc :Athersys announces pricing of public offering of common stock.  Full Article

Athersys announces proposed public offering of common stock
Thursday, 26 Jan 2017 04:28pm EST 

Athersys Inc : Announces proposed public offering of common stock . Intends to offer for sale shares of its common stock, par value $0.001 per share .Intends to use net proceeds for working capital and general corporate purposes, funding towards its phase 3 multistem administration, among others.  Full Article

Athersys, FDA agree on design for ischemic stroke late-stage study
Wednesday, 28 Sep 2016 06:30am EDT 

Athersys Inc :Athersys receives FDA agreement under special protocol assessment for phase 3 study of multistem® treatment for ischemic stroke.  Full Article

Athersys qtrly loss per share $0.08
Tuesday, 9 Aug 2016 04:03pm EDT 

Athersys Inc : Athersys reports second quarter 2016 results . Q2 revenue $600,000 versus $200,000 .Qtrly loss per share $0.08.  Full Article

HEALIOS and Athersys sign licensing contract
Friday, 8 Jan 2016 01:00am EST 

HEALIOS K.K:Signed licensing contract with Athersys, on MultiStem.To pay $15 mln upfront to Athersys and sees to pay up to $30 mln in total as milestone payments.  Full Article

Athersys Inc updates on development strategy in Japan
Wednesday, 21 Oct 2015 06:30am EDT 

Athersys Inc:Says Co and Chugai Pharmaceutical Co., Ltd have ended license agreement between them for exclusive development and commercialization of MultiStem cell therapy for ischemic stroke in Japan.Parties were unable to reach an agreement on the modification of the financial terms of the agreement and on development strategy in Japan, in light of the results from the Phase 2 clinical study.All rights will revert to Athersys, and Athersys will retain the $10 million license fee paid by Chugai.  Full Article

Athersys announces results from phase 2 study for treatment of ischemic stroke
Friday, 17 Apr 2015 05:59am EDT 

Athersys, Inc:Announced interim results from phase 2 clinical study of intravenous administration of MultiStem cell therapy to treat patients who suffered an ischemic stroke.Study results demonstrate favorable safety and tolerability consistent with prior studies.  Full Article

More From Around the Web

BRIEF-Athersys reports pricing of public offering of common stock

* Athersys announces pricing of public offering of common stock Source text for Eikon: Further company coverage: